Table 2.

Univariable and multivariable logistic regression assessing associations with C-11 choline positron emission tomography/computed tomography positivity

	Univariate			Multivariable

Factor	OR	95% CI	p value	OR	95% CI	p value
Age (per yr)	1.00	0.94–1.06	0.9
PSA at diagnosis (per 1 ng/ml)	1.23	1.03–1.46	0.02
Gleason score (ref. 6)
7	1.51	0.61–3.77	0.4
8–10	8.66	1.07–70.15	0.04
Clinical stage (ref. T1)
cT2a–c	2.24	0.74–6.78	0.2
cT3–4	1.43	0.28–7.27	0.7
NCCN risk group (ref. low risk)
Intermediate risk	1.59	0.61–4.15	0.3	1.27	0.45–3.58	0.7
High risk	12.27	1.48–101.66	0.02	10.83	1.26–93.06	0.03
EBRT (ref. BT-containing)	1.24	0.52–2.98	0.6
HT during RT	0.80	0.31–2.47	0.8
Radiation field (ref. prostate only)
Prostate + SV	0.82	0.17–3.96	0.8
Prostate + SV + LN	0.53	0.11–2.67	0.4
PSA nadir (per 1 ng/ml)	1.08	0.67–1.72	0.8
PSA at CholPET scan (per 1 ng/dl)	1.29	1.08–1.53	<0.01
ΔPSA^a (per 1 ng/ml)	1.30	1.08–1.56	<0.01	1.30	1.08–1.57	<0.01
PSA doubling time (per mo)	1.00	0.99–1.01	0.8
PSA velocity (per 1 ng/ml/yr)	1.48	1.01–2.18	0.04

BT = brachytherapy; CholPET = C-11 choline positron emission tomography/computed tomography; CI = confidence interval; EBRT = external beam radiotherapy; HT = hormone therapy; LN = lymph node; NCCN = national comprehensive cancer network; OR = odds ratio; PSA = prostate-specific antigen; ref. = reference; RT = radiation therapy; SV = seminal vesicle.

Difference between PSA at C11 choline PET/CT and PSA nadir.